| pubmed-article:2159372 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2159372 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:2159372 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2159372 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:2159372 | lifeskim:mentions | umls-concept:C0006674 | lld:lifeskim |
| pubmed-article:2159372 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2159372 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:2159372 | pubmed:dateCreated | 1990-6-12 | lld:pubmed |
| pubmed-article:2159372 | pubmed:abstractText | The effects of 1 alpha, 25-dihydroxyvitamin D3 (VD3) on proliferation, differentiation, and macromolecular synthesis in the new Philadelphia chromosome-positive chronic myelogenous leukemia cell line, RWLeu-4, were investigated. Binding of [3H]VD3 was saturable, with approximately 2000-3000 sites/cell, and half-maximal binding occurring at 0.21-0.33 nM. Treatment of RWLeu-4 cells with VD3 induced 24R-hydroxylase activity, a marker of vitamin D3 responsiveness in many tissues. Exposure of RWLeu-4 cells to VD3 also inhibited proliferation and DNA synthesis with a 50% effective dose of 3.5-10 nM within 72 h; in addition, protein and RNA synthesis were inhibited by VD3 treatment. Exposure of RWLeu-4 cells to 5 nM VD3 for 72 h caused 50% of the cells to differentiate into macrophage/monocyte type cells as judged by nitroblue tetrazolium staining and adherence to plastic. Progressive expression of cell surface maturation-specific antigens of the monocyte/macrophage lineage was induced by treatment of RWLeu-4 cells with VD3 for 24 to 72 h at doses that inhibited cellular proliferation. c-myc RNA, which is constitutively expressed in RWLeu-4 cells, increased after 0.5 h of treatment with 50 nM VD3 and then rapidly decreased to barely detectable levels after 4 h of treatment. Finally, the in vitro tyrosine kinase activity associated with the p210bcr-abl oncogene product was decreased approximately 50% by VD3 treatment. Because of the presence of a functional receptor-effector system for VD3 and multiple biological responses to the hormone, these cells provide a unique model system with which to probe the specific effects of VD3 on cell growth and differentiation in chronic myelogenous leukemia. | lld:pubmed |
| pubmed-article:2159372 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2159372 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2159372 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2159372 | pubmed:month | May | lld:pubmed |
| pubmed-article:2159372 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:2159372 | pubmed:author | pubmed-author:CalabresiPP | lld:pubmed |
| pubmed-article:2159372 | pubmed:author | pubmed-author:EilCC | lld:pubmed |
| pubmed-article:2159372 | pubmed:author | pubmed-author:BellWW | lld:pubmed |
| pubmed-article:2159372 | pubmed:author | pubmed-author:PosnerM RMR | lld:pubmed |
| pubmed-article:2159372 | pubmed:author | pubmed-author:HuhnR DRD | lld:pubmed |
| pubmed-article:2159372 | pubmed:author | pubmed-author:LaskyS RSR | lld:pubmed |
| pubmed-article:2159372 | pubmed:author | pubmed-author:WiemannMM | lld:pubmed |
| pubmed-article:2159372 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2159372 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2159372 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:2159372 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2159372 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2159372 | pubmed:pagination | 3087-94 | lld:pubmed |
| pubmed-article:2159372 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:meshHeading | pubmed-meshheading:2159372-... | lld:pubmed |
| pubmed-article:2159372 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2159372 | pubmed:articleTitle | Effects of 1 alpha, 25-dihydroxyvitamin D3 on the human chronic myelogenous leukemia cell line RWLeu-4. | lld:pubmed |
| pubmed-article:2159372 | pubmed:affiliation | Department of Medicine, Roger Williams General Hospital, Providence, Rhode Island. | lld:pubmed |
| pubmed-article:2159372 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2159372 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:2159372 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2159372 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
